Holzkirchen, Germany, February 10, 2014 – Sandoz announced today it has received Norwegian marketing authorization for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and COPD.

The product was first approved in Denmark on December 18th, 2013, with subsequent approvals in Germany, Sweden, Hungary, Romania and Bulgaria.

The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an innovative inhalation device.

Norway has approved the 50/250µg and 50/ …